首页> 美国卫生研究院文献>other >A Xenogeneic-Free Protocol for Isolation and Expansion of Human Adipose Stem Cells for Clinical Uses
【2h】

A Xenogeneic-Free Protocol for Isolation and Expansion of Human Adipose Stem Cells for Clinical Uses

机译:用于临床用途的人脂肪干细胞的分离和扩增的无异种方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human adipose stem cells (hASCs) play a crucial role in the fields of regenerative medicine and tissue engineering for different reasons: the abundance of adipose tissue, their easy harvesting, the ability to multipotent differentiation and the fact that they do not trigger allogeneic blood response or secrete cytokines that act as immunosuppressants. The vast majority of protocols use animal origin reagents, with the underlying risk of transmitting infections by non-human pathogens. We have designed a protocol to isolate and maintain the properties of hASCs avoiding xenogeneic reagents. These changes not only preserve hASCs morphology, but also increase cell proliferation and maintain their stem cell marker profile. On the other hand, human serum albumin (HSA), Tryple® and human Serum (HS), do not affect hASCs multipotent differentiation ability. The amendments introduced do not trigger modifications in the transcriptional profile of hASCs, alterations in key biochemical pathways or malignization. Thus, we have proven that it is possible to isolate and maintain hASCs avoiding animal reagents and, at the same time, preserving crucial culture parameters during long term culture. Thereby we have revealed a novel and effective tool for the improvement of clinical, cell-based therapies.
机译:人类脂肪干细胞(hASC)在再生医学和组织工程领域中起着至关重要的作用,其原因如下:脂肪组织丰富,易于收获,多能分化能力以及它们不会触发同种异体血液反应的事实或分泌起免疫抑制剂作用的细胞因子。绝大多数方案使用动物来源的试剂,具有传播非人类病原体感染的潜在风险。我们设计了一个协议,以隔离和维持hASC的特性,避免使用异种试剂。这些变化不仅保留了hASCs的形态,还增加了细胞增殖并维持了其干细胞标记物的特性。另一方面,人血清白蛋白(HSA)和人血清(HS)不会影响hASC的多能分化能力。引入的修订不会触发hASCs转录谱的修饰,关键生化途径的改变或恶性肿瘤。因此,我们已经证明可以分离和维持hASC,而避免使用动物试剂,同时可以在长期培养过程中保留关键的培养参数。从而,我们揭示了一种新颖有效的工具,用于改善基于细胞的临床疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号